Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Elshad, Hasanov"'
Autor:
Jianjun Gao, Pavlos Msaouel, Nizar Tannir, Eric Jonasch, Matthew Campbell, Amishi Shah, Priya Rao, Omar Alhalabi, Sangeeta Goswami, Nathaniel Wilson, Elshad Hasanov, Jaanki Khandelwal, Devaki S Surasi, Sergio P Klimkowsky, Mohammad J Moussa, Andrew Hahn, Kanishka Sircar
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/404fc62ed4e14a249bf9a56d0fcaefd9
Autor:
Omar Alhalabi, Zaid Soomro, Ryan Sun, Elshad Hasanov, Aya Albittar, Debu Tripathy, Vicente Valero, Nuhad K. Ibrahim
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-5 (2021)
Abstract The development of brain metastases (BMs) in breast cancer (BC) patients remains a challenging complication. Current clinical practice guidelines recommend local treatment of BMs without changing systemic therapy (CST) in patients with stabl
Externí odkaz:
https://doaj.org/article/b13d01d1e9f04a52984ccf0fe8205030
Autor:
Jennifer Wang, Jianjun Gao, Chad Tang, Arlene Siefker-Radtke, Nizar Tannir, Ana Aparicio, Christopher Logothetis, Lianchun Xiao, Matthew Campbell, Omar Alhalabi, Nathaniel Wilson, Elshad Hasanov, John Papadopoulos, Paul Corn, Bogdan Czerniak, Charles Guo, Seungtaek Choi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/ba2000bad25742979f2f4f0f036ce811
42 The role of tissue stiffness in predicting the immunotherapy response in hepatocellular carcinoma
Autor:
Lianchun Xiao, Ahmed Kaseb, Sunyoung Lee, Asif Rashid, Elshad Hasanov, Betul Gok Yavuz, Yehia Mohamed, Aliya Qayyum
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/72fdcb4c7705403ca45c0f5bea76d7d8
Autor:
Omar Alhalabi, Jonathan Thouvenin, Sylvie Négrier, Yann-Alexandre Vano, Luca Campedel, Elshad Hasanov, Ziad Bakouny, Andrew W Hahn, Mehmet Asim Bilen, Pavlos Msaouel, Toni K Choueiri, Srinivas R Viswanathan, Kanishka Sircar, Laurence Albiges, Gabriel G Malouf, Nizar M Tannir
Publikováno v:
The Oncologist. 28:433-439
Background There remains a paucity of data regarding the efficacy of immune checkpoint therapy (ICT) combinations ± vascular endothelial growth factor (VEGF) targeted therapy (TT) in translocation renal cell carcinoma (tRCC). Methods This is a retro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a620b882fa4c0ed74dba09c0bb2a4ac3
https://doi.org/10.1093/oncolo/oyac262
https://doi.org/10.1093/oncolo/oyac262
Autor:
Ahmed O Kaseb, Yinghui Guan, Betul Gok Yavuz, Alexander R Abbas, Shan Lu, Elshad Hasanov, Han Chong Toh, Wendy Verret, Yulei Wang
Publikováno v:
Journal of Hepatocellular Carcinoma. 9:1065-1079
Ahmed O Kaseb,1 Yinghui Guan,2,* Betul Gok Yavuz,1,* Alexander R Abbas,2 Shan Lu,2 Elshad Hasanov,3 Han Chong Toh,4 Wendy Verret,5 Yulei Wang2 1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de1ad6a4677604cfe8046ab8b87d3566
https://doi.org/10.2147/jhc.s369951
https://doi.org/10.2147/jhc.s369951
Autor:
Elshad, Hasanov, Isabel, Pimentel, Mara, Cruellas, Mark A, Lewis, Eric, Jonasch, Judith, Balmaña
Publikováno v:
American Society of Clinical Oncology Educational Book. :808-824
Advances in the genetic basis of different tumors have led to identification of tumor vulnerabilities that can be turn into targeted therapies. In this regard, PARP inhibitors cause synthetic lethality with tumors harboring BRCA1 or BRCA2 genetic alt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75430d57d0bb7698ef1336aad258f47e
https://doi.org/10.1200/edbk_350232
https://doi.org/10.1200/edbk_350232
Autor:
Elshad Hasanov, Debra Nana Yeboa, Mathew D. Tucker, Todd A. Swanson, Thomas Hendrix Beckham, Brian Rini, Chibawanye I. Ene, Merve Hasanov, Sophie Derks, Marion Smits, Shaan Dudani, Daniel Y. C. Heng, Priscilla K. Brastianos, Axel Bex, Sahin Hanalioglu, Jeffrey S. Weinberg, Laure Hirsch, Maria I. Carlo, Ayal Aizer, Paul David Brown, Mehmet Asim Bilen, Eric Lin Chang, Jerry Jaboin, James Brugarolas, Toni K. Choueiri, Michael B. Atkins, Bradley A. McGregor, Lia M. Halasz, Toral R. Patel, Scott G. Soltys, David F. McDermott, James Bradley Elder, Mustafa K. Baskaya, James B. Yu, Robert Timmerman, Michelle Miran Kim, Melike Mut, James Markert, Kathryn Beal, Nizar M. Tannir, George Samandouras, Frederick F. Lang, Rachel Giles, Eric Jonasch
Publikováno v:
CA: A Cancer Journal for Clinicians. 72:454-489
Brain metastases are a challenging manifestation of renal cell carcinoma. We have a limited understanding of brain metastasis tumor and immune biology, drivers of resistance to systemic treatment, and their overall poor prognosis. Current data suppor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3781a977d4b804daa7e38266e935bbb8
https://doi.org/10.3322/caac.21729
https://doi.org/10.3322/caac.21729
Autor:
Ahmed Omar Kaseb, Elshad Hasanov, Hop Sanderson Tran Cao, Lianchun Xiao, Jean-Nicolas Vauthey, Sunyoung S Lee, Betul Gok Yavuz, Yehia I Mohamed, Aliya Qayyum, Sonali Jindal, Fei Duan, Sreyashi Basu, Shalini S Yadav, Courtney Nicholas, Jing Jing Sun, Kanwal Pratap Singh Raghav, Asif Rashid, Kristen Carter, Yun Shin Chun, Ching-Wei David Tzeng, Divya Sakamuri, Li Xu, Ryan Sun, Vittorio Cristini, Laura Beretta, James C Yao, Robert A Wolff, James Patrick Allison, Padmanee Sharma
Publikováno v:
Lancet Gastroenterol Hepatol
Kaseb, A O, Hasanov, E, Cao, H S T, Xiao, L, Vauthey, J N, Lee, S S, Yavuz, B G, Mohamed, Y I, Qayyum, A, Jindal, S, Duan, F, Basu, S, Yadav, S S, Nicholas, C, Sun, J J, Singh Raghav, K P, Rashid, A, Carter, K, Chun, Y S, Tzeng, C W D, Sakamuri, D, Xu, L, Sun, R, Cristini, V, Beretta, L, Yao, J C, Wolff, R A, Allison, J P & Sharma, P 2022, ' Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma : a randomised, open-label, phase 2 trial ', The Lancet Gastroenterology and Hepatology, vol. 7, no. 3, pp. 208-218 . https://doi.org/10.1016/S2468-1253(21)00427-1
Kaseb, A O, Hasanov, E, Cao, H S T, Xiao, L, Vauthey, J N, Lee, S S, Yavuz, B G, Mohamed, Y I, Qayyum, A, Jindal, S, Duan, F, Basu, S, Yadav, S S, Nicholas, C, Sun, J J, Singh Raghav, K P, Rashid, A, Carter, K, Chun, Y S, Tzeng, C W D, Sakamuri, D, Xu, L, Sun, R, Cristini, V, Beretta, L, Yao, J C, Wolff, R A, Allison, J P & Sharma, P 2022, ' Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma : a randomised, open-label, phase 2 trial ', The Lancet Gastroenterology and Hepatology, vol. 7, no. 3, pp. 208-218 . https://doi.org/10.1016/S2468-1253(21)00427-1
Background: Hepatocellular carcinoma has high recurrence rates after surgery; however, there are no approved standard-of-care neoadjuvant or adjuvant therapies. Immunotherapy has been shown to improve survival in advanced hepatocellular carcinoma; we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38276e79aeed564d05882604eb17143a
https://doi.org/10.1016/s2468-1253(21)00427-1
https://doi.org/10.1016/s2468-1253(21)00427-1
Autor:
Vittorio Cristini, Michael A. Curran, Eugene J. Koay, Yehia I. Mohamed, Betul Gok Yavuz, Elshad Hasanov, Sunyoung S. Lee, Ahmed Kaseb
Publikováno v:
Journal of Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common liver cancer and one of the leading causes of cancer-related deaths in the world. Multiple immunotherapeutic approaches have been investigated to date, and immunotherapy has become the new standard of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c532238b8731fd6d2c19b53e1248feaf
http://europepmc.org/articles/PMC8478438
http://europepmc.org/articles/PMC8478438